Welcome!
Thanks for stopping by.
Today I’m sharing information about Tzield (pronounced T-Zield), a groundbreaking medication
that can delay the onset of Type 1 diabetes.
I’ve been living with Type 1 since 1982, when I was a high school senior. Back then, I asked the
nurse how long I’d have diabetes — she didn’t have an answer.
Now, for those who may be at risk, there’s finally some good news.
�
� What is Tzield?
- FDA Approved: November 2022
- Manufacturer: Sanofi (since 2023, made in Washington State)
- Purpose: Protects pancreatic beta cells from immune attack to delay Type 1 diabetes
onset - Not for: People with Type 2 diabetes
�
� Who Might Be Eligible?
Tzield may be prescribed if:
✅ You do not have typical symptoms of Type 1 diabetes
✅ You have two or more diabetes-related antibodies (immune system attacking beta cells)
✅ You have abnormal blood sugar levels caused by ongoing beta cell loss
�
� Effectiveness - Tzield: Delays onset by ~4 years
- Placebo: ~2 years
That’s two extra years of living without full Type 1 diabetes.
�
� How Treatment Works - One 14-day course of IV infusions
- Each infusion: 30 min to 4 hrs
- Dosage ramps up over time
- If a dose is missed, treatment picks up where you left off
⚠ Possible Side Effects - Leukopenia – Low white blood cell count
- Lymphopenia – Low lymphocyte count (increased infection risk)
- Rash
- Headache
�
� Note: If lymphopenia develops, treatment may be stopped.
�
� Cost & Insurance (as of 7/30/25) - Tzield: ~$193,900 per 14-day treatment
- Annual Type 1 diabetes care: Several thousand to tens of thousands of dollars
Coverage options: - Many insurance plans cover Tzield
- Medicare Part B covers teplizumab-mzwv
- Patient support: Tzield Compass Program
�
� Other Research - Baricitinib – being studied for preserving beta cell function in newly diagnosed Type 1
diabetes
�
� Important Disclaimer
This blog is informational only and not medical advice. Always consult your doctor before
making health decisions.
While I work to ensure accuracy, errors are possible. Use this information at your own risk.
�
� Interested in advertising here? Contact me!
✍ Author:
Julie – Living with Type 1 diabetes since 1982.
Passionate about sharing resources and research for those at risk.
